On January 7, Gelonghui reported that CSPC PHARMA (01093.HK) announced the approval of the SYH2059 tablets developed by the group by the National Medical Products Administration of China, allowing clinical trials to be conducted in China.
This product was developed by the group's small molecule drug innovation design platform and is a brand new, completely independently patented and highly active and selective phosphodiesterase 4B (PDE4B) inhibitor. PDE4B inhibitors exert anti-inflammatory and anti-fibrotic effects by regulating the release of inflammatory Indicators, inhibiting the proliferation and differentiation of fibroblasts, etc. The approved clinical indications for this drug are interstitial lung disease (including but not limited to idiopathic pulmonary fibrosis and progressive pulmonary fibrosis). Preclinical studies have shown that this product's selectivity and activity against the PDE4B target are significantly superior to similar target drugs, with markedly better efficacy in disease animal models compared to existing drugs, and it shows good pharmacokinetic characteristics and safety.
Currently, there are few drugs on the market for the treatment of interstitial lung disease, and patients' treatment benefits are limited; this product is expected to become an effective treatment for this disease, holding significant clinical development value.
